Chemical Genetic Targeting of the LRRK2 GTPase Domain
This study demonstrates that chemically targeting the LRRK2 Roc-COR GTPase domain offers a viable alternative therapeutic strategy to partially downregulate kinase activity and potentially mitigate the on-target toxicities associated with full kinase inhibition in Parkinson's disease.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Parkinson's disease is a condition that slowly robs the body of its ability to move smoothly, often starting with a tremor in the hand. For many patients, the root cause lies in a single gene called LRRK2. This gene provides instructions for building a massive protein that acts like a molecular machine inside cells. Normally, this machine helps regulate how cells communicate and move, but when the gene carries a mutation, the machine runs too hot, producing too much activity that eventually damages the brain. For years, scientists have tried to fix this by building drugs that act as a brake on the machine's engine, specifically targeting the part that generates the energy. However, these drugs have faced a difficult problem: when they slow down the engine too much, they also cause severe side effects in the lungs and kidneys, making it hard to use them safely in people. This has left researchers searching for a different way to control the machine, one that might offer a gentler, more precise adjustment rather than a complete shutdown.
The protein in question is a complex structure with several distinct parts, including an engine known as a kinase and a control switch known as a GTPase. While the engine has been the primary focus of drug development, the control switch has remained largely unexplored as a therapeutic target. In this new study, researchers set out to see if they could target this control switch instead. Their goal was to find a way to engage the switch to naturally dial down the engine's speed, hoping to avoid the harsh side effects caused by directly jamming the engine. To do this, they used a clever strategy called chemical genetics, which involves slightly altering the protein so that existing drugs, designed for a different protein, could bind to it. They took a drug originally developed to treat a specific type of cancer by targeting a different protein, and engineered the Parkinson's-related protein to accept it.
The team first created a version of the LRRK2 protein that had been modified with a few specific changes to its structure, essentially creating a new pocket where the drug could fit. They tested this modified protein in the lab and found that the drug, known as divarasib, could indeed bind to it. Using high-resolution imaging, they confirmed that the drug settled into the pocket exactly as it does in its original target, forming a stable connection. This proved that the control switch of the Parkinson's protein could be physically engaged by a drug, a significant step forward since these types of switches have long been considered too difficult to target.
When the researchers introduced this modified protein into human cells and added the drug, they observed a fascinating and unexpected result. The drug successfully reduced the activity of the protein's engine, but it did not stop it completely. Instead of turning the machine off, the drug seemed to tune it down to a lower, safer level. This outcome was distinct from what happens when scientists use traditional drugs that block the engine directly. Those traditional drugs tend to shut the machine down entirely, which leads to the toxic side effects seen in earlier trials. In contrast, engaging the control switch with the drug reduced the harmful overactivity without eliminating the protein's necessary functions. The researchers also discovered that a specific change in the protein's structure, which they had introduced to make the drug bind, was actually responsible for making the protein run too fast in the first place. By fixing this structural flaw with a second, compensating change, they could calm the protein down even without the drug, confirming that the control switch and the engine are tightly linked.
The study suggests that the control switch acts not as a simple on-off button, but as a fine-tuning dial that regulates how hard the engine works. When the drug binds to the switch, it disrupts the protein's internal structure in a way that naturally slows the engine, yet leaves enough activity for the cell to function normally. This finding offers a promising new path for treating Parkinson's disease. It suggests that future therapies might not need to completely silence the protein to be effective. Instead, by targeting the control switch, doctors might be able to restore the protein to a healthy balance, potentially avoiding the dangerous side effects that have stalled previous treatments. While this work was done in cells and not yet in people, it provides a strong proof of concept that targeting the control switch is a viable and potentially safer alternative to the current approach of directly blocking the engine.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.